Sanofi to Acquire Biotech Company Synthorx for $ 2.5 Billion

France: Takeover Sanofi to Acquire Biotech Company Synthorx for $ 2.5 Billion

11.12.2019Editor: MA Alexander Stark

Sanofi and Synthorx entered into a definitive agreement under which the French group will acquire all of the outstanding shares of the company for an aggregate equity value of approximately $ 2.5 billion.

Related Vendor

Sanofi-Aventis Deutschland GmbH

“This acquisition fits perfectly with our strategy to build a portfolio of high-quality assets and to lead with innovation," says Paul Hudson, Chief Executive Officer, Sanofi.
(Source: Peter Hurley Photo)

Paris/France; San Diego/California — Sanofi will acquire the clinical-stage biotechnology company Synthorx. The transaction was unanimously approved by both Boards of Directors. According to Sanofi CEO Paul Hudson, this acquisition fits perfectly with the strategy to build a portfolio of high-quality assets and to lead with innovation. Additionally, it is aligned with the group's goal to build their oncology franchise with potentially practice-changing medicines and novel combinations.

Synthorx’s novel discovery platform has already produced a molecule that has the potential to become a foundation of the next generation of immuno-oncology combination therapies. By selectively expanding the numbers of effector T-cells and natural killer cells in the body, THOR-707 can be combined with Sanofi's current oncology medicines and their emerging pipeline of immuno-modulatory agents for treating cancer. Moreover, the company’s pipeline of engineered lymphokines holds great promise not only for oncology but also for addressing many autoimmune and inflammatory diseases, says John Reed, M.D., Ph.D., Global Head of Research & Development at Sanofi.

Sanofi's new plant ist one of the first digital manufacturing facilities in the world to use continuous, intensified biologics production technology. (Sanofi)

Under the terms of the merger agreement, Sanofi will commence a cash tender offer to acquire all of the outstanding shares of Synthorx common stock for $ 68 per share in cash for a total enterprise value of approximately $ 2.35 billion. The $ 68 per share acquisition price represents a 172 % premium to Synthorx’s closing price on December 6, 2019.

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Stand vom 23.03.2021

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.

(ID:46284870)